News

New LENSai API by BioStrand Integrates Large Language Models with Health Data for Advanced Drug Development

BioStrand, a subsidiary of ImmunoPrecise Antibodies Ltd. (IPA), has launched its new LENSai API software, designed to integrate large databases …

Continue ›››

Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics

Envisagenics, an AI-enabled biotechnology firm specializing in RNA splicing therapeutics, has announced the completion of its Series B funding round. …

Continue ›››

FDA and CluePoints Extend Collaboration to Enhance Clinical Trial Data Integrity with AI and Machine Learning

The Food and Drug Administration (FDA) and CluePoints, a provider of statistical and AI-driven software solutions, have entered a new …

Continue ›››

Nobel Laureate Inaugurates New Molecular Devices Facility for Manufacturing Patient-Derived Organoids

Molecular Devices, LLC, a leader in high-performance life science solutions, has officially opened its state-of-the-art facility in Cardiff, UK. This …

Continue ›››

Merck KGaA Partners with Biolojic Design for $376M Antibody-Drug Conjugate Development

Merck KGaA has entered into a collaboration with Biolojic Design to develop new oncology and immunology therapeutics using Biolojic’s AI-driven …

Continue ›››

Paige Introduces Multi-Modal AI for Enhanced Precision Oncology and Drug Discovery

Paige, a provider of digital pathology solutions and AI applications, has launched a new service line leveraging its Foundation Models. …

Continue ›››

Insmed Announces Positive Results from ASPEN Study of Brensocatib in Bronchiectasis Patients

Insmed Incorporated has reported positive topline results from the ASPEN study, a pivotal Phase III clinical trial evaluating the efficacy, …

Continue ›››

ExpressionEdits Raises $13M for AI-Based Protein Expression Technology

ExpressionEdits, a biotechnology company focused on optimizing protein expression through AI and proprietary intronization technology, has raised $13 million in …

Continue ›››

DeepCure Unveils AI-Driven Chemical Synthesis Platform

DeepCure, a company specializing in AI-driven therapeutic discovery, has introduced a development in chemical synthesis with its Inspired Chemistry™ platform. …

Continue ›››

Owkin Expands Oncology Pipeline with AI and EP2/EP4 Dual Inhibitor from Idorsia

Owkin, a pioneering TechBio company leveraging advanced causal* AI for precision drug discovery, has announced a significant expansion of its …

Continue ›››

Tempus AI Files S-1 Registration to Go Public

Tempus AI has officially filed its S-1 registration statement with the Securities and Exchange Commission (SEC), marking a significant step …

Continue ›››

Sanofi, Formation Bio, and OpenAI Partner to Innovate Drug Development with AI

Sanofi, Formation Bio, and OpenAI have announced a pioneering collaboration aimed at accelerating drug development using artificial intelligence (AI). This …

Continue ›››